We found that CD36, SMAD9, H2-DMB2, CYP4A12a, CYP4A12b, Ccr1, C3, MAPK1, MAPK3, CASP3, PPARG, IL10 might be the key targets for dapagliflozin in treating DN and these genes were evidently enriched in pathways including PPAR signaling pathway, Chemokine signaling pathway, TGF-β signaling pathway, etc. The gene discussed is TGFB1; the disease is liver dysplastic nodule.